Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation
Abstract The incidence of dry eye disease (DED) has been increasing annually worldwide, creating an urgent need for new therapies. Due to the multifactorial mechanism underlying DED, traditional medications focused on decreasing ocular surface inflammation have been unable to address all the harmful...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202411172 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593504557072384 |
|---|---|
| author | Yin Zhang Tinglian Zhou Kai Wang Chenqi Luo Dan Chen Zeen Lv Haijie Han Ke Yao |
| author_facet | Yin Zhang Tinglian Zhou Kai Wang Chenqi Luo Dan Chen Zeen Lv Haijie Han Ke Yao |
| author_sort | Yin Zhang |
| collection | DOAJ |
| description | Abstract The incidence of dry eye disease (DED) has been increasing annually worldwide, creating an urgent need for new therapies. Due to the multifactorial mechanism underlying DED, traditional medications focused on decreasing ocular surface inflammation have been unable to address all the harmful factors and fail to achieve a complete clinical cure. Ferroptosis, a new form of programmed cell death characterized by lipid peroxidation, has become a pivotal contributor to dry eye oxidative stress‐driven pathology. Therefore, therapeutic targeting of ferroptosis may be an attractive option for dry eye management. Herein, a sialic acid‐targeting peptide‐modified liposome loaded with Cyclosporine A (CsA), a typical anti‐inflammatory drug, and Ferrostatin‐1 (Fer‐1), a selective ferroptosis inhibitor, is developed termed as CF@SNPs, for combing and sustaining DED treatment. This multifunctional liposomal encapsulation demonstrates excellent aqueous solubility; moreover, the sialic acid‐targeting peptide prolongs ocular surface retention, further enhancing therapeutic efficacy. The CF@SNPs treatment comprehensively alleviates DED symptoms, including improving corneal defects, augmenting goblet cell count, and restoring tear secretion. Specifically, CF@SNPs attenuate dry eye pathology by suppressing p53‐SLC7A11‐GSH‐dependent ferroptosis and TNF‐α‐associated inflammatory cascades, accompanied by favorable biocompatibility in vivo. These results underscore the promising potential of this superior nano‐formulation for DED pharmacotherapy. |
| format | Article |
| id | doaj-art-da8458eec4e544a8bc87d4f704349ed0 |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-da8458eec4e544a8bc87d4f704349ed02025-01-20T13:04:19ZengWileyAdvanced Science2198-38442025-01-01123n/an/a10.1002/advs.202411172Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and InflammationYin Zhang0Tinglian Zhou1Kai Wang2Chenqi Luo3Dan Chen4Zeen Lv5Haijie Han6Ke Yao7Eye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaEye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaEye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaEye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaEye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaEye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaEye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaEye Center the Second Affiliated Hospital School of Medicine Zhejiang University Zhejiang Provincial Key Laboratory of Ophthalmology Zhejiang Provincial Clinical Research Center for Eye Diseases Zhejiang Provincial Engineering Institute on Eye Diseases Hangzhou 310009 ChinaAbstract The incidence of dry eye disease (DED) has been increasing annually worldwide, creating an urgent need for new therapies. Due to the multifactorial mechanism underlying DED, traditional medications focused on decreasing ocular surface inflammation have been unable to address all the harmful factors and fail to achieve a complete clinical cure. Ferroptosis, a new form of programmed cell death characterized by lipid peroxidation, has become a pivotal contributor to dry eye oxidative stress‐driven pathology. Therefore, therapeutic targeting of ferroptosis may be an attractive option for dry eye management. Herein, a sialic acid‐targeting peptide‐modified liposome loaded with Cyclosporine A (CsA), a typical anti‐inflammatory drug, and Ferrostatin‐1 (Fer‐1), a selective ferroptosis inhibitor, is developed termed as CF@SNPs, for combing and sustaining DED treatment. This multifunctional liposomal encapsulation demonstrates excellent aqueous solubility; moreover, the sialic acid‐targeting peptide prolongs ocular surface retention, further enhancing therapeutic efficacy. The CF@SNPs treatment comprehensively alleviates DED symptoms, including improving corneal defects, augmenting goblet cell count, and restoring tear secretion. Specifically, CF@SNPs attenuate dry eye pathology by suppressing p53‐SLC7A11‐GSH‐dependent ferroptosis and TNF‐α‐associated inflammatory cascades, accompanied by favorable biocompatibility in vivo. These results underscore the promising potential of this superior nano‐formulation for DED pharmacotherapy.https://doi.org/10.1002/advs.202411172cyclosporine Adry eye diseaseferroptosisferrostatin‐1oxidative stress |
| spellingShingle | Yin Zhang Tinglian Zhou Kai Wang Chenqi Luo Dan Chen Zeen Lv Haijie Han Ke Yao Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation Advanced Science cyclosporine A dry eye disease ferroptosis ferrostatin‐1 oxidative stress |
| title | Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation |
| title_full | Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation |
| title_fullStr | Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation |
| title_full_unstemmed | Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation |
| title_short | Corneal Mucin‐Targeting Liposome Nanoplatforms Enable Effective Treatment of Dry Eye Diseases by Integrated Regulation of Ferroptosis and Inflammation |
| title_sort | corneal mucin targeting liposome nanoplatforms enable effective treatment of dry eye diseases by integrated regulation of ferroptosis and inflammation |
| topic | cyclosporine A dry eye disease ferroptosis ferrostatin‐1 oxidative stress |
| url | https://doi.org/10.1002/advs.202411172 |
| work_keys_str_mv | AT yinzhang cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation AT tinglianzhou cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation AT kaiwang cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation AT chenqiluo cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation AT danchen cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation AT zeenlv cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation AT haijiehan cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation AT keyao cornealmucintargetingliposomenanoplatformsenableeffectivetreatmentofdryeyediseasesbyintegratedregulationofferroptosisandinflammation |